The role of rapid diagnostic tests in managing adults with pneumonia in low-resource settings.
In well-resourced settings the systematic use of rapid diagnostics tests (e.g. pneumococcal urinary antigen test) that define the causal pathogen to direct therapy has not resulted in significantly improved outcomes in adults with pneumonia. The management of pneumonia in many low-resource settings is complicated by a substantial burden of tuberculosis and HIV-associated opportunistic infections, in addition to the usual spectrum of pathogens seen in well-resourced settings. Clinical features alone do not reliably distinguish between these different aetiologies and physicians often have to treat empirically. Given the limitations in diagnostic laboratory capability present in most low-resource settings, rapid and point-of-care diagnostic tests could become valuable tools to guide treatment decisions. Pneumococcal andLegionellaurinary antigen tests are specific and moderately sensitive, but their utility in low-resource settings is uncertain. The Cepheid Xpert MTB/RIF platform and rapid assays for urinary lipoarabinomannan can substantially speed up tuberculosis diagnosis; the current challenge is to translate this into earlier treatment and hopefully improve patient outcome. In HIV-infected patients, 1-3-β-D-glucan is a serum marker ofPneumocystis jiroveciiinfection with excellent sensitivity. Further studies are needed to assess the clinical utility and cost-effectiveness of these rapid diagnostics assays when they incorporated into treatment algorithms.
Malawi Liverpool Wellcome Trust Clinical Research Facility, Blantyre, Malawi; Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Stephen J
SJ
Aston
1-3-β-D-glucan; BinaxNOW Streptococcus pneumoniae urinary antigen; Xpert MTB/RIF; lipoarabinomannan